- Home
- GAME vs OTLK Comparison
GAME vs OTLK Comparison
Compare GAME & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | OTLK |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 29.2M |
| IPO Year | 2024 | 2016 |
Fundamental Metrics
Financial Performance| Metric | GAME | OTLK |
|---|---|---|
| Price | $0.25 | $0.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 846.7K | ★ 2.5M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.72 | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,198,101.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,606.43 |
| Revenue Next Year | $17.89 | $93.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.00 | N/A |
| 52 Week Low | $0.26 | $0.16 |
| 52 Week High | $2.87 | $3.39 |
Technical Indicators
Market Signals| Indicator | GAME | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 25.79 |
| Support Level | N/A | N/A |
| Resistance Level | $0.32 | $0.46 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 3.63 | 15.66 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.